Atria Investments Inc Acquires Shares of 1,592 TransMedics Group, Inc. $TMDX

Atria Investments Inc bought a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,592 shares of the company’s stock, valued at approximately $213,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Valmark Advisers Inc. raised its position in TransMedics Group by 34.6% in the second quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock worth $1,301,000 after acquiring an additional 2,496 shares during the period. Raymond James Financial Inc. grew its position in shares of TransMedics Group by 135.8% during the 1st quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock valued at $9,782,000 after acquiring an additional 83,722 shares during the period. Northern Trust Corp increased its stake in shares of TransMedics Group by 2.1% during the 1st quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock worth $24,353,000 after purchasing an additional 7,341 shares during the last quarter. Montanaro Asset Management Ltd raised its holdings in shares of TransMedics Group by 9.7% in the 1st quarter. Montanaro Asset Management Ltd now owns 153,675 shares of the company’s stock worth $10,339,000 after purchasing an additional 13,640 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in TransMedics Group by 2.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company’s stock valued at $20,478,000 after purchasing an additional 6,934 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMDX has been the subject of a number of recent research reports. Evercore ISI initiated coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price for the company. Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a research note on Thursday, October 30th. Jefferies Financial Group assumed coverage on TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Finally, Stifel Nicolaus started coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price for the company. Eight analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $130.73.

TransMedics Group Stock Performance

Shares of TMDX opened at $115.55 on Friday. The stock’s 50-day simple moving average is $118.60 and its 200 day simple moving average is $119.42. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of 46.78 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 EPS. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 4,142 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the sale, the director owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. This represents a 59.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.